The ratio of hepatitis C virus genotypes in patients with HCV infection in St. Petersburg in 2024–2025

Read full text Summarise with VIRAT
Authors: Denis A. Gusev, Н. В. Дунаева, A. E. Safonova
Cited by: 0
References: 7

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The ratio of hepatitis C virus (HCV) genotypes in the Russian Federation and in individual regions is a dynamic process that requires regular research within each region of the country. Such studies have become particularly relevant in the context of widespread access of patients with HCV infection to modern antiviral therapy. The aim of the study was to analyze the dynamics of the ratio of different HCV genotypes in patients with HCV infection in St. Petersburg in 2024-2025, as well as to evaluate gender and age indicators and the severity of liver fibrotic changes. Materials and methods. The retrospective continuous cross-sectional study included all patients with chronic HCV infection who were prescribed antiviral therapy (HTP) at the Botkin Clinical Infectious Diseases Hospital from 01.01.2024 to 31.12.2025 (n=4122). During the studied period, antiviral therapy was performed using various antiviral drugs (genotype-specific and pangenotypic), in accordance with current clinical guidelines of the Ministry of Health of the Russian Federation. Results. In 2024, the frequency of genotype 3a was 37.6%, 1b – 50.8%, 1a – 3.7%, 2 – 7.5%, unverified – 0.4%, mixed genotypes were not registered. In 2025– 3a – 46.8%, 1b – 37.8%, 1a – 5.1%, 2 – 9.9%, unverified – 0.2%, mixed – 0.1% (χ 2 =71.244, p

Fields of Study & Subjects

Hepatitis C virus research Animal Virus Infections Studies Helicobacter pylori-related gastroenterology studies

Publication details

Journal / source
Journal Infectology
Volume
18
Issue
1
Pages
46–53
Publication date
27 March 2026
Language
EN